Sign In
Buy PHGE
$0.184
-0.0046 (-2.44%)
At Close: Jul 31, 2026
BiomX Accelerates Defense Technology Buildout with DFSL Acquisition
09:20am, Monday, 13'th Apr 2026
Acquisition expands BiomX's defense portfolio with aligned capabilities designed to integrate across detection, analysis, and response, reinforcing its position in AI-enabled security systems Acquisit
BiomX Inc. (PHGE) Shareholder/Analyst Call Prepared Remarks Transcript
11:11am, Friday, 10'th Apr 2026
BiomX Inc. (PHGE) Shareholder/Analyst Call Prepared Remarks Transcript
BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications
08:30am, Friday, 10'th Apr 2026
Targets $81B command-and-control and video analytics markets by 2030, driven by real-time situational awareness in defense environments Targets $81B command-and-control and video analytics markets by
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
10:48am, Tuesday, 31'st Mar 2026
The platform delivers ~99% accuracy in real-world deployments across defense and infrastructure; When closed, the transaction value is estimated at approximately $45 million The platform delivers ~99%
BiomX Adds Former Mossad Deputy to Advisory Board
09:28am, Monday, 30'th Mar 2026
Dr. Ehud (Udi) Levi brings decades of intelligence experience as Company evaluates expansion into security, defense, and counter-UAS technologies Dr. Ehud (Udi) Levi brings decades of intelligence exp
BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
04:30pm, Friday, 27'th Mar 2026
Discloses “Going Concern” Explanatory Paragraph in Auditor's Report Discloses “Going Concern” Explanatory Paragraph in Auditor's Report
BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations
08:48am, Thursday, 26'th Mar 2026
Initiative marks entry into Israel's rapidly growing autonomous AI defense, firefighting and first response activities Initiative marks entry into Israel's rapidly growing autonomous AI defense, firef
BiomX CEO Issues Letter to Stockholders
09:15am, Thursday, 19'th Mar 2026
CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunities DOVER, Del., March 19, 2026 /PRNe
BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth
09:00am, Monday, 09'th Mar 2026
Seasoned financial leaders join BiomX to support strategic execution and advancement of the company DOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE American: PHGE),
BiomX Issues Statement Regarding Recent Common Stock Trading Activity
01:41pm, Tuesday, 27'th Jan 2026
NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therap
All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy
01:01pm, Monday, 29'th Dec 2025
BiomX (PHGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BiomX Announces $3.0 Million Private Placement
08:00am, Monday, 29'th Dec 2025
Proceeds to Support the Company's Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives Proceeds to Support the Company's Assessment of Opportunities to Advance
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
07:30am, Monday, 08'th Dec 2025
Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review
01:23pm, Wednesday, 26'th Nov 2025
BiomX Inc. (NYSE: PHGE) on Tuesday announced that the U.S. Food and Drug Administration (FDA) is continuing its evaluation of the nebulizer device used for drug administration in the company's Phase 2
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
04:40pm, Tuesday, 25'th Nov 2025
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used i
